Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: A 1-year, observational cohort study

CNS Drugs

Volumn 25, Issue 11, 2011, Pages 971-981

  Comini Frota, Elizabeth R ^a   Teixeira, Antonio L ^a   Angelo, Janaína P A ^a   Andrade, Marcus V ^a   Brum, Doralina G ^b   Kaimen Maciel, Damacio R ^c   Foss, Norma T ^b   Donadi, Eduardo A ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Chemokines; CXC chemokines; Interferon beta 1a; Interferon beta 1b; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; BIOCHEMICAL MARKER; CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON BETA SERINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; GENDER; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATHOGENESIS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; CHEMOKINE CCL2; CHEMOKINE CCL4; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHEMOKINES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; YOUNG ADULT;

EID: 80555154358     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11595060-000000000-00000     Document Type: Article

References (47)

1. Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005; 252 Suppl. 5: v3-9 (Pubitemid 41532349)
2. Al-Omaishi J, Bashir R, Gendelman HE. The cellular immunology of multiple sclerosis. J Leukoc Biol 1999 Apr; 65 (4): 444-52 (Pubitemid 29160171)
3. Trebst C, Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 2001 Dec; 58 (12): 1975-80 (Pubitemid 33143976)
4. Szczucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis: potential targets for new therapies. Acta Neurol Scand 2007 Mar; 115 (3): 137-46 (Pubitemid 46219205)
5. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998 Feb 12; 338 (7): 436-45 (Pubitemid 28135672)
6. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001 Feb; 2 (2): 102-7 (Pubitemid 33707926)
7. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006 Feb 9; 354 (6): 610-21 (Pubitemid 43209108)
8. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42
9. Kivisakk P, Trebst C, Eckstein DJ, et al. Chemokine-based therapies for MS: how do we get there from here? Trends Immunol 2001 Nov; 22 (11): 591-3
10. Muller DM, Pender MP, Greer JM. Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. Curr Drug Targets 2004 Sep; 3 (3): 279-90 (Pubitemid 39206656)
11. Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurol 2006 Nov 28; 67 (10): 1880-3 (Pubitemid 44900777)
12. Hamann I, Zipp F, Infante-Duarte C. Therapeutic targeting of chemokine signaling in multiple sclerosis. J Neurol Sci 2008 Aug 13; 274: 31-8
13. Simpson J, Rezaie P, Newcombe J, et al. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000 Aug 1; 108 (1-2): 192-200 (Pubitemid 30438767)
14. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999 Mar; 103 (6): 807-15 (Pubitemid 29152626)
15. Elhofy A, Wang J, Tani M, et al. Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis. J Leukoc Biol 2005 Feb; 77 (2): 229-37 (Pubitemid 40315057)
16. Putheti P, Morris M, Stawiarz L, et al. Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables. Eur J Neurol 2003 Sep; 10 (5): 529-35 (Pubitemid 38021468)
17. Sorensen TL, Ransohoff RM, Strieter RM, et al. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol 2004 Jul; 11 (7): 445-9 (Pubitemid 39037029)
18. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 Jul; 50 (1): 121-7
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 1983 Nov; 33 (11): 1444-52 (Pubitemid 14237132)
20. Lublin FD. Clinical features and diagnosis of multiple sclerosis. Neurol Clin 2005 Feb; 23 (1): 1-15 (Pubitemid 40126912)
21. Bakshi R, Hutton GJ, Miller JR, et al. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurol 2004 Dec 14; 63 (11 Suppl. 5): S3-11
22. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, I. Adult brain. Clin Exp Pharmacol Physiol 1999 Jan; 26 (1): 11-9 (Pubitemid 29051338)
23. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001 Apr 2; 115 (1-2): 192-8 (Pubitemid 32245668)
24. Sorensen TL, Sellebjerg F, Jensen CV, et al. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001 Nov; 8 (6): 665-72 (Pubitemid 35015232)
25. Furlan R, Rovaris M, Martinelli Boneschi F, et al. Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol 2005 Aug; 165 (1-2): 192-200 (Pubitemid 40984638)
26. Moreira MA, Tilbery CP, Monteiro LP, et al. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 2006 Aug; 114 (2): 109-13 (Pubitemid 44034258)
27. Moreira MA, Souza AL, Lana-Peixoto MA, et al. Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis. Braz J Med Biol Res 2006 Apr; 39 (4): 441-5
28. Balashov KE, Rottman JB, Weiner HL, et al. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999 Jun 8; 96 (12): 6873-8 (Pubitemid 29274977)
29. Buttmann M, Merzyn C, Rieckmann P. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 2004 Nov; 156 (1-2): 195-203 (Pubitemid 39304200)
30. Buttmann M, Goebeler M, Toksoy A, et al. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol 2005 Nov; 168 (1-2): 175-82 (Pubitemid 41396416)
31. Cepok S, Schreiber H, Hoffmann S, et al. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 2009Oct; 66 (10): 1216-23
32. Krakauer M, Sorensen PS, Khademi M, et al. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand J Immunol 2006 Aug; 64 (2): 155-63 (Pubitemid 44034320)
33. Buttmann M, Berberich-Siebelt F, SerflingE, et al. Interferonbeta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells. J Vasc Res 2007; 44 (1): 51-60 (Pubitemid 46105692)
34. Klein RS, Izikson L, Means T, et al. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 2004 Jan 1; 172 (1): 550-9 (Pubitemid 38020512)
35. Liu MT, Keirstead HS, Lane TE. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol 2001 Oct 1; 167 (7): 4091-7 (Pubitemid 32910857)
36. Muller M, Carter SL, Hofer MJ, et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007 Sep 1; 179 (5): 2774-86
37. Kanda N, Watanabe S. Regulatory roles of sex hormones in cutaneous biology and immunology. J Dermatol Sci 2005 Apr; 38 (1): 1-7 (Pubitemid 40410625)
38. Mo R, Chen J, Grolleau-Julius A, et al. Estrogen regulates CCR gene expression and function in T lymphocytes. J Immunol 2005 May 15; 174 (10): 6023-9 (Pubitemid 40663789)
39. Iarlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol 2000 Jul 10; 107 (1): 100-7 (Pubitemid 30243135)
40. Zang YC, Halder JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES andMIP-1alpha by interferon-beta. J Neuroimmunol 2001 Jan 1; 112 (1-2): 174-80
41. Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004 Sep; 251 Suppl. 5: v12-29
42. Achiron A, Barak Y, Gail M, et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005 Feb; 89 (3): 265-70 (Pubitemid 43293074)
43. Hughes MD.Multiple sclerosis and pregnancy. Neurol Clin 2004 Nov; 22 (4): 757-69
44. Franciotta D, Zardini E, Ravaglia S, et al. Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. J Neurol Sci 2006 Sep 25; 247 (2): 202-7 (Pubitemid 44301264)
45. Bartosik-Psujek H, Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005 Jan; 12 (1): 49-54
46. Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002 Apr; 72 (4): 498-502
47. Sindern E, Niederkinkhaus Y, Henschel M, et al. Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2001 Aug; 104 (2): 88-91 (Pubitemid 32977008)